Scientific Publications and Presentations

Science That Moves Neuroscience Forward

Our scientific publications reflect our commitment to advancing neuroscience through rigorous research, transparent data sharing, and ongoing collaboration with the scientific community.

Search by Keyword

Search Facet

Filter by Focus Area

Focus Area Filter
  • Vormatrigine
  • Relutrigine
  • Ulixacaltamide
  • Elsunersen
  • Other

Filter by Focus Area

Focus Area Filter Dropdown

Filter by Year

Year Filter
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021

Filter by Year

Year Filter - Dropdown

Filter by Meeting

Meeting Filter
  • AAN Annual Meeting
  • AES Annual Meeting
  • Behind the Seizure Scientific Exhibit
  • Drug Discovery for ION Channels XXII Meeting
  • EEC Meeting
  • IAPRD Meeting
  • IEC Meeting
  • MDS Congress
  • Oligonucleotides for CNS Meeting
  • Syngap1 Conference

Filter by Meeting

Meeting Filter - Dropdown

Antisense Oligonucleotide Treatment in a Preterm Infant With Early-Onset SCN2A Developmental and Epileptic Encephalopathy

2022 | Drug Discovery for ION Channels XXII Meeting

Using Dynamic Action Potential Clamp Modeling of NaV1.2 Variants to Support the Prediction of Clinical Phenotype in DEE

2022 | AES Annual Meeting | Behind the Seizure Scientific Exhibit

Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy

2023 | Oligonucleotides for CNS Meeting

Leveraging Preclinical Models To Inform Clinical Trial Strategy in SCN2A Developmental and Epileptic Encephalopathy

2024 | EEC Meeting

Significant Seizure Reduction in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy following Treatment with Elsunersen, a Novel Antisense Oligonucleotide: Findings from the EMBRAVE Study

2025 | IEC Meeting

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Cases in a Preterm Infant with Refractory Status Epilepticus

2025 | IEC Meeting

Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy

2025 | AES Annual Meeting

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A DEE: Emergency Use Cases in a Preterm Infant with Refractory Status Epilepticus

2026 | AAN Annual Meeting

Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy

2026 | AAN Annual Meeting

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus

Explore More